April 12, 2017
Gene silencing shows promise for treating two fatal neurological disorders
NIH-funded preclinical studies suggest designer drug may treat ALS and spinocerebellar ataxia 2.
Pharmaceuticals, Biotechnology and Life Sciences
NIH-funded preclinical studies suggest designer drug may treat ALS and spinocerebellar ataxia 2.
Scientists have long been interested in how the vascular system — the body’s network of large and small blood vessels — may be involved in the onset and progression of Alzheimer’s disease and related dementias.